Then Even, the report says, CDC personnel did not notify officials up the management chain until July 9. [The report] blames too little written records and failing to check out established best practices. The laboratory had no approved team-specific operating process of the work it had been doing, the report adds . This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an unbiased news service editorially, is a program of the Kaiser Family members Foundation, a nonpartisan healthcare policy research corporation unaffiliated with Kaiser Permanente.. CDC report blames researcher’s haste for bird flu virus mishandling Friday Information outlets covered the release of the report. The Washington Post: CDC Scientist Took Shortcuts Handling Deadly Bird Flu Virus, Investigation Finds An investigation into the mistaken shipment of deadly bird flu virus from a government laboratory earlier this year found that a scientist took shortcuts to increase the work and unintentionally contaminated the samples, friday the Centers for Disease Control and Avoidance reported.The research underlying this technology was originally executed at Dartmouth College by Professor Charles Sentman, and has been released in numerous peer-reviewed publications such as Journal of Immunology, Cancer Research and Blood. NKG2D CAR T-Cell received an Investigational New Medication clearance, beneath the name CM-CS1, from the U.S. Food and Medication Administration in July 2014 for the Phase I medical trial in hematologic cancers. Dr. Christian Homsy, CEO of Cardio3 BioSciences, commented: We are extremely pleased to initiate enrollment of the first Stage I trial of our CAR T-Cell therapy plan with lead product candidate NKG2D CAR T-Cell, in-line with our disclosed clinical development plan previously.